Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Raloxifene HCL Clear all
Completed Phase 4 Interventional Results available

Raloxifene and Rimostil for Perimenopause-Related Depression

NCT00030147
View directory record Official record
Conditions
Perimenopausal Depression, Depression
Interventions
Raloxifene, Rimostil, Transdermal Estradiol, Placebo skin patch and placebo tablets
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
40 Years to 60 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2016 · Synced Sep 13, 2026, 9:50 AM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 13, 2026, 9:50 AM EDT
Terminated No phase listed Observational

Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene

NCT00847821
View directory record Official record
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2010 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 2Phase 3 Interventional

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

NCT00065767
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 13, 2026, 9:50 AM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

NCT00163137
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 4 Interventional

Long Term Effects of Raloxifene Treatment on Bone Quality

NCT00532428
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Raloxifene HCL, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 80 Years · Female only
Enrollment
7,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

NCT00004915
View directory record Official record
Conditions
Endometrial Cancer
Interventions
raloxifene
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 13, 2026, 9:50 AM EDT
Completed No phase listed Observational

Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

NCT04736693
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic Acid
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older · Female only
Enrollment
18,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 13, 2026, 9:50 AM EDT
Terminated Not applicable Interventional Results available

Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

NCT01607320
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen Alternatives Study

NCT00108238
View directory record Official record
Conditions
Healthy
Interventions
Estradiol followed by progesterone, Raloxifene
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

NCT00003906
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
35 Years and older · Female only
Enrollment
19,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
492
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis

NCT00001848
View directory record Official record
Conditions
Endometriosis, Pelvic Pain
Interventions
Raloxifene
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 4 Interventional

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 4 Interventional

Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, raloxifene HCl, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Maywood, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 4 Interventional Results available

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cognition in the Study of Tamoxifen and Raloxifene

NCT00687102
View directory record Official record
Conditions
Cognition, Aging
Interventions
tamoxifen, raloxifene
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years and older · Female only
Enrollment
1,498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
127
States / cities
Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

NCT00332553
View directory record Official record
Conditions
Vasomotor Symptoms, Endometrial Safety
Interventions
Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 13, 2026, 9:50 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

NCT06062810
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene - Usual, Raloxifene - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 13, 2026, 9:50 AM EDT
Not yet recruiting Phase 2 Interventional

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

NCT07470606
View directory record Official record
Conditions
Brain Tumor
Interventions
Memantine, Raloxifene
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Early Phase 1 Interventional

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

NCT01050842
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions
bicalutamide, raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

AFTER: Altering Fat Through Estrogen and Raloxifene

NCT00149604
View directory record Official record
Conditions
Postmenopause
Interventions
conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
Drug · Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years to 70 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Sep 13, 2026, 9:50 AM EDT
Completed Phase 3 Interventional

Raloxifene Use for The Heart

NCT00190593
View directory record Official record
Conditions
Cardiovascular Diseases, Breast Neoplasms
Interventions
raloxifene, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Sep 13, 2026, 9:50 AM EDT